Spondyloarthritis & psoriatic arthritis
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis
Authors' conclusion
Bimekizumab ranked favourably among b/tsDMARDs for efficacy on joint, skin and MDA outcomes, and showed comparable safety
Study context
- Population
- b/tsDMARD-naïve and TNF inhibitor (TNFi)-experienced patients with PsA (safety in a mixed population)41 randomized controlled trials (RCTs), 22 b/tsDMARDs
- Comparison
- Bimekizumab vs other b/tsDMARDs
- Outcome
- Efficacy ranking (SUCRA)
- Follow-up
- Weeks 12-24
Methodological detailsBayesian network meta-analysis (NMA), SUCRA ranking, Systematic literature review, most recent update 1 January 2023
- Bayesian NMA
- SUCRA ranking
- Systematic literature review, most recent update 1 January 2023
Pooled result
As reported in the abstract
- Minimal disease activity (MDA): rank in b/tsDMARD-naïve
- 1st
- MDA: rank in TNFi-experienced
- 2nd
- ACR20/50/70: ranks in b/tsDMARD-naïve
- 6th, 5th and 3rd
- ACR20/50/70: ranks in TNFi-experienced
- 1st, 2nd and 1st
- PASI 90/100: ranks in b/tsDMARD-naïve
- 2nd and 1st
- PASI 90/100: ranks in TNFi-experienced
- 1st and 2nd
Safety
Serious adverse events · Weeks 12-24
- Bimekizumab comparable to b/tsDMARDs
- Mixed population
Original publication
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). Published 13 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →